Description
Vitaminum C Biowet Puławy 100 mg/ml solution for injection for horses, cattle, pigs, sheep, dogs, cats and foxes
Statement of the active substance(s) and other ingredient(s)
Each ml contains:
Active substance:
Ascorbic acid 100 mg
Clear, yellow solution.
Target species
Horse, cattle, pig, sheep, dog, cat, fox.
Indications for use
Treatment of vitamin C deficiency, support in antibiotic therapy, treatment of digestive disorders, during pregnancy and exposure to stress, weakening and exhaustion. Support in the treatment of urinary tract infections.
Contraindications
Calcium oxalate stone.
Special warnings
Special precautions for safe use in the target species:
Intramuscular injection may lead to topical irritation (especially in horses).
Significant pain may occur during injection of the product.
More acidic urine may induce precipitation of urates, oxalates and citrates, leading to the formation of stone in the urinary tract.
In animals diagnosed with diabetes and suffering from excessive absorption of iron from the gastrointestinal tract, avoid administration of ascorbates in doses higher than recommended.
Parenteral administration of ascorbic acid in doses higher than recommended leads to false positive laboratory results pointing to the presence of glucose in the blood.
Keep special caution when using vitamin C with deferoxamine in old animals. If there is a need to administer the two medicines at the same time, it is recommended to administer the ascorbic acid two hours after the infusion of deferoxamine.
In case of intravenous administration, warm the product to body temperature and inject slowly.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Accidental self-injection of this veterinary medicinal product poses no threat to the person administering the product.
Pregnancy and lactation:
The product can be used during pregnancy and lactation.
Interaction with other medicinal products and other forms of interaction:
Ascorbic acid adds to the effect of coumarin anticoagulants. It increases iron absorption. Flavonoid glycosides enhance the effect of vitamin C.
By making urine more acidic, ascorbic acid reduces the antibacterial effect of aminoglycosides and macrolides. Simultaneous administration of vitamin C and iron-binding deferoxamine used for treating secondary hemochromatosis and transfusion hemosiderosis, may lead to iron overload, primarily in cardiac cells, which produces rhythm and conductions disorders. When administered intravenously, ascorbic acid reduces the half-life of salicylamide.
Simultaneous administration of oxytocin and ascorbic acid impairs the ascorbic acid’s capability to cross the placenta to get to the foetus.
Overdose:
Administration of ascorbic acid in doses exceeding the recommended doses may lead to urine acidification, which leads to impaired excretion of weak acids and bases. Excessive intake of vitamin C may cause diarrhoea and reduced absorption of anticoagulants from the gastrointestinal tract.
Administration of multiple doses of ascorbic acid exceeding 4 g may lead to inactivation of vitamin B12, transient reduction of neutrophil’s phagocytosis and bactericidal function, excessive absorption of iron ions and formation of kidney stone.
Major incompatibilities:
Ascorbic acid is incompatible with sodium bicarbonate, sodium salicylate, sodium nitrate, theobromine, hexamethylenetetramine (methenamine), chlorpromazine hydrochloride, methylprednisolone sodium succinate.
Do not mix the ascorbic acid solution with other veterinary medicinal products for injection.
Adverse events
Horses, cattle, pigs, sheep, dogs, cats and foxes:
| Frequency unknown (cannot be determined based on the available data): | Kidney stone 1 |
1 may occur in animals predisposed to develop kidney stone.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorization holder using the contact details found at the end of this leaflet, or via your national reporting system:
Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Al. Jerozolimskie 181C
PL 02-222 Warsaw
Tel.: +48 22 49 21 687
Fax: +48 22 49 21 605
E-mail: pw@urpl.gov.pl
Website: https://smz.ezdrowie.gov.pl
Dosage for each target species, route(s) and method(s) of administration
Intravenous or intramuscular use.
This veterinary medicinal product is to be administered in the following daily doses:
Cattle, horses 5-10 mg/kg b.w. i.e. 0.05 – 0.1 ml/kg b.w.
Pigs, sheep 8-16 mg/kg b.w. i.e. 0.08 – 0.16 ml/kg b.w.
Dogs, cats, foxes 10-20 mg/kg b.w. i.e. 0.1 – 0.2 ml/kg b.w.
This veterinary medicinal product should be administered for 5 to 7 days (it is recommended to administer half a dose twice daily)
Advice on correct administration
In case of intravenous administration, warm the product to body temperature and inject slowly.
Withdrawal period(s)
Meat and offal:
Horse, cattle, pig, sheep – zero days
Milk:
Cattle, sheep – zero days
Special precautions for storage
Keep out of the sight and reach of children.
Store below 25°C. Protect from light. Do not freeze.
Do not use this veterinary medicinal product after the expiry date which is stated on the label after “Exp”. The expiry date refers to the last day of that month.
Shelf-life after first opening the immediate packaging: 28 days.
Special precautions for disposal
Medicines should not be disposed of via wastewater or household waste.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.
Ask your veterinary surgeon how to dispose of medicines no longer required.
Classification of veterinary medicinal products
Veterinary medicinal product subject to a veterinary prescription.
Marketing authorisation numbers and pack sizes
991/00
Pack sizes: 100 ml
Date on which the package leaflet was last revised
23/05/2025
Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).
Contact details
Marketing authorisation holder and manufacturer responsible for batch release:
Biowet Puławy Sp. z o.o.
Henryka Arciucha 2
24-100 Puławy
Poland
Tel./Fax: + 48 (81) 886 33 53, Tel: + 48 (81) 888 91 00
e-mail: sekretariat@biowet.pl
Contact details to report suspected adverse events:
Biowet Puławy Sp. z o.o.
Henryka Arciucha 2
24-100 Puławy
Poland
Tel.: + 48 (81) 888 91 33, Tel: +48 509 750 444
e-mail: biowet@biowet.pl
SPC: 2025-05-23
2025-07-17
